If you or a loved one, or even a friend are looking into filing claims from the diabetes drug Onglyza (saxagliptin) for causing health issues that have heart failure or death, then our class action lawyers are ready to help with your Washington DC Onglyza lawsuit.
AstraZeneca is the business that makes Onglyza, an FDA-approved medication intended to treat type 2 diabetes. Onglyza is a DPP-4 inhibitor, the type of medications made to reduce blood glucose levels and inhibit diabetic complications in adults that have type two diabetes.
In a recent FDA advisory committee meeting, it had been passed that the labeling used on Onglyza be upgraded together with clear warnings about the chance of developing heart failure. It was a warning which wasn’t contained the drug’s labels previously.
If you, a loved one, or relative took Onglyza and suffered heart failure, or your loved one died, you may have grounds for asking for reimbursement against the manufactures of Onglyza. Know that AstraZeneca is a huge business and has a team of trusted Mass Tort lawyers representing its own interests once the company is slapped with lawsuits.
What Is Onglyza?
Onglyza got the nod from the FDA in July 2009 as a medication that can be employed in the treatment of type 2 diabetes. As a DDP-4 (dipeptidyl peptidase-4) inhibitor, a sort of medication also known as an incretin mimetic, Onglyza has elements that stimulate the pancreas to increase insulin production following the user eats a meal. Januvia is another medication, such as Onglyza, that’s used as a treatment for type 2 diabetes. With the rise in insulin levels, the body can process glucose (sugars) and be sure they are kept within the normal range.
FDA approved using Onglyza after reviewing the results of eight clinical trials achieved by manufacturers AstraZeneca Pharmaceuticals LP. The trial included a safety study meant to prove that Onglyza wasn’t associated with any significant risk of cardiovascular disease.
However, recent investigations of the outcomes of a clinical trial on Onglyza accomplished by FDA experts found that concerning issues that linked the medicine to heart disease risks. The trial (the SAVOR study), which was sponsored by AstraZeneca, had over 16,000 participants. The participants either had a history or prone to developing cardiovascular disease. Some of them were awarded Onglyza, and others obtained Placebo.
The researchers tracked the participants’ health advancement for around two decades. The results showed many of the patients that utilized Onglyza were hospitalized for heart failure compared to those who obtained Placebo. The Onglyza users possess a 27% higher risk of heart disease, heart failure, or related complications.
The outcomes necessitated stricter scrutiny on the medication by the FDA.
How Is Onglyza Linked To Heart Failure?
Cardiovascular disease is one of the leading health problems that lead to the passing of both women and men in the united states. The CDC says there are nearly 610,000 deaths attributed to cardiovascular disease annually. Should you do the math, that amounts to 1 every four deaths in the United States annually.
Heart failure happens when the heart fails to pump as much blood as is required throughout the entire body. It’s a type of cardiovascular disease where the body receives an inadequate supply of blood. Thus, less oxygen to its organs, thereby crippling their collective purpose. If not treated, heart failure progresses and contributes to fatal health issues with fatal consequences.
For people who have type 2 diabetes and are using Onglyza, the link between their health issues and the medication is alarming. The FDA began an investigation procedure into the medication and how it increases the risk of heart failure; this is after grown concerns across the United States. The analysis unearthed worrying issues that led to further warnings of heart failure risk linked with the usage of Onglyza in addition to Kombiglyze XR.
How Is Onglyza Linked to Pancreatic Cancer?
Because of how Onglyza stimulates the pancreas to release more insulin, that’s the reason the medication was linked to the consumers confronting a prospective increase in the chance of pancreatitis and pancreatic cancer.
A study performed in 2013 that centered on how DDP-4 inhibitors affected the pancreas discovered that participants who had type 2 diabetes and obesity were utilizing Onglyza have a greater probability of having an enlarged pancreas. They also have an increased risk of having precancerous cellular changes in their own pancreas, suggesting a considerable probability of developing pancreatic cancer. According to the research, it was also found that tumors (precancerous growths) are highly likely to require surgical interventions and that the patients using medication like Onglyza showed a greater chance of desire pancreatic surgery.
The FDA hauled another drug security awake in March of 2013, saying it had been analyzing findings of a study that indicated the substantial likelihood of pancreatitis and precancerous cellular changes in individuals who were utilizing incretin mimetic to treat their type 2 diabetes.
A later study conducted in 2014 in which researchers examined data from a significant clinical trial on Onglyza discovered no indications of pancreatic cancer or the risk of pancreatitis. They, nevertheless, recommended further research to make certain they get conclusive findings that indicate pancreatic safety concerning using incretin mimetics.
Can Onglyza Cause Thyroid Cancer?
Victoza, an incretin mimetic that shares similarities with Onglyza, was discovered to cause malignant thyroid gland as well as acute pancreatitis in rodents which were given the medication in”clinically relevant” dosages. Back in June 2011, the FDA issued a safety warning stating the probability of thyroid cancer from using Victoza. Furthermore, the FDA has received several reports of people diagnosed with thyroid cancer after using prescribed incretin mimetics such as Byetta (exenatide) and Januvia (sitagliptin).
Has There Been A Recall Of Onglyza Or Incretin Mimetics?
No recall was announced, and it’s unlikely for you to be issued any time soon. The recalls seem unforthcoming, yet the reality of heart failure, cancers, and other potentially deadly health problems can’t be overlooked or swept under the rug. The identical fate is due to Onglyza and other incretin mimetics found to increase the chance of heart failure. But it appears that the only important step taken for these drugs with such serious side effects is to require that the producers include additional safety warnings on their products’ labels.
Are There Any Continuing Class Action Lawsuits Involving Kombiglyze, Onglyza, Or Any Incretin Mimetic?
Drug injury lawsuits are rarely filed as”class action,” where a few plaintiffs will represent the others that have cases against a drug company. Alternatively, you will fill this kind of issue individually.
In January 2018, the U.S Judicial Panel on Multidistrict Litigation ordered the”consolidation” of existing lawsuits filed against Kombiglyze and Onglyza from the U.S District Court for the Eastern District of Kentucky. From May 2018, there were approximately 100 of these cases that formed consolidated litigation called the MDL 2809.
Some of the most notable negative health issues associated with the use of Onglyza include:
- Heart failure
- Kidney problems
- Thyroid cancer
- Pancreatic cancer
Apart from the severe side effects Mentioned Previously, Onglyza is also connected to the following moderate to moderate health hazard:
- Urinary tract infections
- Rashes and Infection
- Upper respiratory tract infections
Can You File a Lawsuit Against the Maker of Onglyza Without an FDA Recall?
The FDA panel recommends the addition of clear warnings about the increased risk of heart failure on the labels of Onglyza. But this directive has many inquiring why the warning was not included when the item was released ten years ago.
And if this is the present condition of affairs, then it means lots of the patients that took Onglyza over the past decade were unaware of the potential health risk. They, therefore, might have suffered serious side effects, not knowing the cause.
The law stipulates that drug manufacturers should be accountable for ensuring the public is duly informed before they release a product to the market. It makes them liable for any negative outcomes and functions to safeguard the general public from unnecessary health problems.
And as per the law, patients who took Onglyza and endured heart failure can find reimbursement because the pharmaceutical companies making the medication don’t provide the public with sufficient safety warnings about this kind of probable outcome.
Get Assistance With a Washington DC Onglyza Lawsuit
In the event that you or a loved one used Onglyza and suffered heart failure, hospitalization, or your relative died because of using the medication, the dedicated class action attorneys at our firm are here to assist. We have represented different people from across the nation.
Thus, we’ve got a deep comprehension of how pharmaceuticals like Bristol Meyers Squibb and AstraZeneca are expected, by legislation, to make sure physicians and patients are fully conscious of the risk connected with the use of their medications. Failure to do this means that these manufacturers are liable for harm that people who use their drugs suffer.
At our firm, we’ve dealt with cases linked to Onglyza and possess a deep understanding of its flaws. Thus, we are your very best bet if you want to manage the manufacturers of Onglyza and triumph. Contact our law offices today at 855-938-0980 for a totally free consultation, case review, and learn more about your rights.